condition Transplant – Solid Organ

Overview

Transplant is the procedure in which a new organ or cells are placed in the body to cure a disease. In a solid organ transplant, an organ like a kidney, liver, or heart is taken from one person and placed in another. After the transplant, the person who received the organ has to take several different medications for the rest of their life to keep their body from rejecting the new organ and to prevent different infections.

Drug Therapies

  • CellCept

    CellCept (mycophenolate mofetil)

    CellCept (mycophenolate mofetil) is a prodrug of mycophenolic acid, an antiproliferative agent approved to prevent rejection of a transplanted organ. Because of its mechanism, CellCept is also widely used in the management of certain autoimmune disorders.
    Manufacturer:
    Genentech
    Route of Administration: 
    Oral
    Site of Care:
    Outpatient
    Website: 
    • https://www.cellcept.com/
    Enrollment Forms:
    Synergen Prescription Form
    Patient Support Form

    Approved Indication:

    prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogenic kidney, heart, or liver transplants, in combination with other immunosuppressants

    Conditions:

    • Solid Organ Transplant

      Therapeutic Area:

      • Gastroenterology
      • Rheumatology
      • Dermatology
      • Hepatology
      • Nephrology
      less details
    • Cresemba

      Cresemba (isavuconazonium sulfate)

      Cresemba (isavuconazonium sulfate) is an azole antifungal medication given orally or intravenously to treat invasive aspergillosis or invasive mucormycosis.
      Manufacturer:
      Astellas
      Route of Administration: 
      Oral, Intravenous
      Site of Care:
      Outpatient
      Website: 
      • https://www.cresemba.com/
      phone: 
      1-800-477-6472
      Enrollment Forms:
      Synergen Prescription Form
      Patient Support Form

      Approved Indication:

      treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients 6 years of age and older who weigh at least 16 kilograms

      Conditions:

      • Invasive Aspergillosis
      • Mucormycosis
        less details
      • Envarsus XR

        Envarsus XR (tacrolimus extended-release)

        Envarsus XR (tacrolimus extended-release) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
        Manufacturer:
        Veloxis Pharmaceuticals
        Route of Administration: 
        Oral
        Site of Care:
        Outpatient
        Website: 
        • https://www.envarsusxr.com/
        phone: 
        1-844-VELOXIS (1-844-835-6947)
        Enrollment Forms:
        Synergen Prescription Form
        Patient Support Form

        Approved Indication:

        • prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants
        • prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants

        Conditions:

        • Solid Organ Transplant

          Therapeutic Area:

          • Hepatology
          less details
        • Gengraf

          Gengraf (cyclosporine, modified)

          Gengraf (cyclosporine, modified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
          Manufacturer:
          Misc.
          Route of Administration: 
          Oral
          Site of Care:
          Outpatient
          Website: 
            Enrollment Forms:
            Synergen Prescription Form

            Approved Indication:

            • prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants
            • treatment of patients with severe, active rheumatoid arthritis where the disease has not adequately responded to methotrexate
            • treatment of adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy or for whom other systemic therapies are contraindicated or cannot be tolerated

            Conditions:

            • Solid Organ Transplant
            • Rheumatoid Arthritis
            • Plaque Psoriasis

              Therapeutic Area:

              • Cardiology
              • Dermatology
              • Hepatology
              • Nephrology
              • Rheumatology
              • Transplant
              less details
            • Imuran

              Imuran (azathioprine)

              Imuran (azathioprine) is a prodrug of 6-mercaptopurine, a neucleoside metabolic inhibitor approved to prevent rejection of a transplanted organ or to reduce signs and symptoms of certain autoimmune disorders.
              Manufacturer:
              Sebela Pharmaceuticals Inc.
              Route of Administration: 
              Oral
              Site of Care:
              Outpatient
              Website: 
                Enrollment Forms:
                Synergen Prescription Form

                Approved Indication:

                • adjunct for the prevention of rejection in renal homotransplantation
                • treatment of active rheumatoid arthritis to reduce signs and symptoms

                Conditions:

                • solid organ transplant
                • rheumatoid arthritis

                  Therapeutic Area:

                  • Rheumatology
                  • Nephrology
                  • Solid Organ Transplant
                  less details
                • Livtencity

                  Livtencity (maribavir)

                  Livtencity (maribavir) is an antiviral medication approved by the FDA to treat infection with cytomegalovirus (CMV) in patients who have received a transplant and have failed or are resistant to other antivirals.
                  Manufacturer:
                  Takeda
                  Route of Administration: 
                  Oral
                  Site of Care:
                  Outpatient
                  Website: 
                  • https://www.livtencity.com/
                  phone: 
                  1-855-268-1825
                  Enrollment Forms:
                  Synergen Prescription Form
                  Patient Support Form

                  Approved Indication:

                  treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (+/- genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet

                  Conditions:

                  • Post-Transplant Cytomegalovirus (CMV) Infection

                    Therapeutic Area:

                    • Infectious disease
                    less details
                  • Mepron

                    Mepron (atovaquone)

                    Mepron (atovaquone) is a quinone antibiotic used primarily to prevent and treat Pneumocystis jirovecii pneumonia.
                    Manufacturer:
                    GSK
                    Route of Administration: 
                    Oral
                    Site of Care:
                    Outpatient
                    Website: 
                      Enrollment Forms:
                      Synergen Prescription Form

                      Approved Indication:

                      • prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX)
                      • treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX

                      Conditions:

                      • Pneumocystis
                      • jirovecii
                      • pneumonia

                        Therapeutic Area:

                        • Infectious Disease
                        less details
                      • Myfortic

                        Myfortic (mycophenolic acid)

                        Myfortic (mycophenolic acid) is the active form of mycophenolate, an antiproliferative agent approved to prevent rejection of a transplanted organ. Compared with CellCept, it is associated with lower incidence of gastrointestinal side effects and improved tolerability.
                        Manufacturer:
                        Novartis
                        Route of Administration: 
                        Oral
                        Site of Care:
                        Outpatient
                        Website: 
                          Enrollment Forms:
                          Synergen Prescription Form
                          Patient Support Form

                          Approved Indication:

                          prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant, in combination with other immunosuppressants

                          Conditions:

                          • Solid Organ Transplant

                            Therapeutic Area:

                            • Nephrology
                            less details
                          • Neoral

                            Neoral (cyclosporine, modified)

                            Neoral (cyclosporine, modified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
                            Manufacturer:
                            misc.
                            Route of Administration: 
                            Oral
                            Site of Care:
                            Outpatient
                            Website: 
                              Enrollment Forms:
                              Synergen Prescription Form

                              Approved Indication:

                              • prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants
                              • treatment of patients with severe, active rheumatoid arthritis where the disease has not adequately responded to methotrexate
                              • treatment of adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy or for whom other systemic therapies are contraindicated or cannot be tolerated

                              Conditions:

                              • Solid Organ Transplant
                              • Rheumatoid Arthritis
                              • Plaque Psoriasis

                                Therapeutic Area:

                                • Cardiology
                                • Dermatology
                                • Hepatology
                                • Nephrology
                                • Rheumatology
                                • Transplant
                                less details
                              • Posaconazole

                                posaconazole

                                Posaconazole is an azole antifungal medication given orally to treat Candida infections of the mouth or throat or orally or intravenously to prevent Aspergillus or Candida infections in patients with compromised immune systems.
                                Manufacturer:
                                Misc
                                Route of Administration: 
                                Oral
                                Site of Care:
                                Outpatient
                                Website: 
                                  Enrollment Forms:
                                  Synergen Prescription Form

                                  Approved Indication:

                                  • prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy
                                  • treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole

                                  Conditions:

                                  • Aspergillosis
                                  • Candidiasis
                                    less details
                                  • Prevymis

                                    Prevymis (letermovir)

                                    Prevymis (letermovir) is an antiviral medication given intravenously or by mouth to prevent infection with cytomegalovirus (CMV) in patients who have received a transplant.
                                    Manufacturer:
                                    Merck
                                    Route of Administration: 
                                    Oral
                                    Site of Care:
                                    Outpatient
                                    Website: 
                                    • https://www.prevymis.com/
                                    phone: 
                                    855-404-5278
                                    Enrollment Forms:
                                    Synergen Prescription Form
                                    Patient Support Form

                                    Approved Indication:

                                    • prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogenic hematopoietic stem cell transplant
                                    • prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-])

                                    Conditions:

                                    • Post-Transplant Cytomegalovirus (CMV) Prophylaxis

                                      Therapeutic Area:

                                      • Infectious disease
                                      less details
                                    • Prograf

                                      Prograf (tacrolimus)

                                      Prograf (tacrolimus) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
                                      Manufacturer:
                                      Astellas
                                      Route of Administration: 
                                      Oral
                                      Site of Care:
                                      Outpatient
                                      Website: 
                                      • https://www.prograf.com/
                                      Enrollment Forms:
                                      Synergen Prescription Form

                                      Approved Indication:

                                      prophylaxis of organ rejection in adult and pediatric patients receiving allogenic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants

                                      Conditions:

                                      • Solid Organ Transplant

                                        Therapeutic Area:

                                        • Cardiology
                                        • Hepatology
                                        • Nephrology
                                        • Pulmonology
                                        • Transplant
                                        less details
                                      • Rapamune

                                        Rapamune (sirolimus)

                                        Rapamune (sirolimus) inhibits the mammalian target of rapamycin (mTOR) to suppress the immune system and prevent the rejection of a transplanted organ.
                                        Manufacturer:
                                        Pfizer
                                        Route of Administration: 
                                        Oral
                                        Site of Care:
                                        Outpatient
                                        Website: 
                                        • https://www.pfizer.com/products/product-detail/rapamune
                                        Enrollment Forms:
                                        Synergen Prescription Form

                                        Approved Indication:

                                        • prophylaxis of organ rejection in combination with cyclosporine and corticosteroids in patients aged ≥ 13 years receiving renal transplants
                                        • treatment of patients with lymphangioleiomyomatosis

                                        Conditions:

                                        • Solid organ transplant
                                        • lymphangioleiomyomatosis

                                          Therapeutic Area:

                                          • Nephrology
                                          • Pulmonary
                                          • Solid Organ Transplant
                                          less details
                                        • Sandimmune

                                          Sandimmune (cyclosporine, unmodified)

                                          Sandimmune (cyclosporine, UNmodified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.
                                          Manufacturer:
                                          Misc.
                                          Route of Administration: 
                                          Oral, Intravenous
                                          Site of Care:
                                          Outpatient, Inpatient
                                          Website: 
                                            Enrollment Forms:
                                            Synergen Prescription Form

                                            Approved Indication:

                                            prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants in combination with adrenal corticosteroids

                                            Conditions:

                                            • Solid Organ Transplant

                                              Therapeutic Area:

                                              • Cardiology
                                              • Hepatology
                                              • Nephrology
                                              • Transplant
                                              less details
                                            • Sulfamethoxazole-Trimethoprim

                                              sulfamethoxazole / trimethoprim

                                              Sulfamethoxazole/trimethoprim is an antibiotic combination product used, among other indications, to prevent and treat Pneumocystis jiroveci pneumonia in patients with compromised immune systems.
                                              Manufacturer:
                                              Misc
                                              Route of Administration: 
                                              Oral, Intravenous
                                              Site of Care:
                                              Outpatient
                                              Website: 
                                                Enrollment Forms:
                                                Synergen Prescription Form

                                                Approved Indication:

                                                • treatment of urinary tract infections due to susceptible strains of Escherichia coli, Klebsiella sp, Enterobacter sp, Morganella morganii, Proteus mirabilis, or Proteus vulgaris
                                                • treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, sulfamethoxazole/trimethoprim offers some advantage over the use of other antimicrobial agents
                                                • treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole/trimethoprim could offer some advantage over the use of a single antimicrobial agent
                                                • treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated
                                                • treatment of documented Pneumocystis jiroveci pneumonia and for prophylaxis against P. jiroveci pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing P. jiroveci pneumonia
                                                • treatment of traveler’s diarrhea due to susceptible strains of enterotoxigenic E. coli

                                                Conditions:

                                                • Urinary Tract Infections
                                                • Acute Otitis Media
                                                • Bronchitis
                                                • Shigellosis
                                                • Pneumocystis Jiroveci Pneumonia
                                                • Traveler’s Diarrhea

                                                  Therapeutic Area:

                                                  • Infectious Disease
                                                  less details
                                                • Valacyclovir

                                                  valacyclovir

                                                  Valacyclovir is an antiviral medication used to treat or prevent infections by various strains of the herpes virus.
                                                  Manufacturer:
                                                  Misc
                                                  Route of Administration: 
                                                  Oral
                                                  Site of Care:
                                                  Outpatient
                                                  Website: 
                                                    Enrollment Forms:
                                                    Synergen Prescription Form

                                                    Approved Indication:

                                                    • cold sores (Herpes labialis) in adult and pediatric patients
                                                    • treatment of initial or recurrent genital herpes in immunocompetent adult patients
                                                    • suppression of genital herpes in immunocompent or HIV-infected adult patients
                                                    • reduction of transmission of genital herpes in adult patients
                                                    • Herpes zoster in adult patients
                                                    • chickenpox in pediatric patients

                                                    Conditions:

                                                    • Herpes Labialis Infection
                                                    • Herpes Zoster Infection
                                                    • Genital Herpes
                                                    • Cold Sores
                                                    • Chickenpox

                                                      Therapeutic Area:

                                                      • Infectious Disease
                                                      less details
                                                    • Valganciclovir

                                                      valganciclovir

                                                      Valganciclovir is an antiviral medication that targets cytomegalovirus (CMV) and is used to treat and/or prevent CMV infection in patients who have received a transplant.
                                                      Manufacturer:
                                                      Misc
                                                      Route of Administration: 
                                                      Oral
                                                      Site of Care:
                                                      Outpatient
                                                      Website: 
                                                        Enrollment Forms:
                                                        Synergen Prescription Form

                                                        Approved Indication:

                                                        • treatment of cytomegalovirus retinitis in adult patients with acquired immunodeficiency syndrome (AIDS)
                                                        • prevention of cytomegalovirus disease in adult kidney, heart, or kidney-pancrease transplant patients at high risk
                                                        • prevention of cytomegalovirus disease in pediatric kidney or heart transplant patients at high risk

                                                        Conditions:

                                                        • Cytomegalovirus

                                                          Therapeutic Area:

                                                          • Infectious Disease
                                                          less details
                                                        • Voriconazole

                                                          voriconazole

                                                          Voriconazole is a triazole antifungal agent given intravenously or by mouth to treat invasive fungal infections caused by Aspergillus sp, Candida sp, Fusarium sp, and others. In immunocompromised patients, voriconazole is also used to prevent these infections.
                                                          Manufacturer:
                                                          Misc
                                                          Route of Administration: 
                                                          Oral, Intravenous
                                                          Site of Care:
                                                          Outpatient
                                                          Website: 
                                                            Enrollment Forms:
                                                            Synergen Prescription Form

                                                            Approved Indication:

                                                            • treatment of invasive aspergillosis
                                                            • treatment of Candidemia in nonneutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds
                                                            • treatment of esophageal candidiasis
                                                            • treatment of serious fungal infections caused by Scedosporium apiospermum and Fusium spp. in patients intolerant of or refractory to other therapy

                                                            Conditions:

                                                            • Aspergillosis
                                                            • Candidiasis

                                                              Therapeutic Area:

                                                              • Infectious Disease
                                                              less details
                                                            • Zortress

                                                              Zortress (everolimus)

                                                              Zortress (everolimus) inhibits the mammalian target of rapamycin (mTOR) to suppress the immune system and prevent the rejection of a transplanted organ.
                                                              Manufacturer:
                                                              Novartis
                                                              Route of Administration: 
                                                              Oral
                                                              Site of Care:
                                                              Outpatient
                                                              Website: 
                                                              • https://www.novartis.com/us-en/content/zortress%C2%AE-tablets
                                                              Enrollment Forms:
                                                              Synergen Prescription Form

                                                              Approved Indication:

                                                              • prophylaxis of organ rejection in combination with basiliximab, cyclosporine, and corticosteroids in adult patients at low-moderate immunologic risk after kidney transplant
                                                              • prophylaxis of organ rejection in combination with tacrolimus and corticosteroids in adult patients at least 30 days after liver transplant

                                                              Conditions:

                                                              • Solid organ transplant

                                                                Therapeutic Area:

                                                                • Hepatology
                                                                • Nephrology
                                                                • Solid Organ Transplant
                                                                less details

                                                              Resources

                                                              Understanding a diagnosis can feel overwhelming. These resources link to well-established organizations, for in-depth education, research, and support.

                                                              American Transplant Foundation
                                                              Georgia Transplant Foundation
                                                              National Bone Marrow Transplant Link

                                                              Stay Connected

                                                              Get the latest news and updates

                                                              Contact Us Now